Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 5761-5770 Newer>

HBS Working Knowledge July 13, 2009	Diagnosing the Public Health Care Alternative With deep experience in health insurance reform, HBS faculty describe how improved competition in insurance plans could improve value for patients.
The Motley Fool July 13, 2009 Brian Orelli	Finally! It's a Win, Isn't It? Eli Lilly and marketing partner Daiichi Sankyo finally got a Food and Drug Administration approval of their blood thinner, Effient (prasugrel), on Friday afternoon.
Pharmaceutical Executive July 1, 2009	Swallowing the Innovator's Rx Capitalize on the new age in healthcare with "disruptive innovation."
Pharmaceutical Executive July 1, 2009	French Revolution Chris Viehbacher's first fast and furious six months at the top of Sanofi-Aventis have heads spinning... and rolling.
Pharmaceutical Executive July 1, 2009	The Pharmerging Future A guide to grabbing growth in seven "pharmerging" markets.
Pharmaceutical Executive July 1, 2009 Megan Svensen	Get Organized What community organizing can teach pharma marketers about building a brand.
Pharmaceutical Executive July 1, 2009 Stan Bernard	Forget Brand vs. Brand--This is War Increasingly, pharma companies are expanding from brand vs. brand to battle at the franchise, portfolio, and corporate levels.
Pharmaceutical Executive July 1, 2009 Patrick Clinton	What to Buy In the long run, pharma wants to sell health, not just drugs.
Pharmaceutical Executive July 1, 2009 Jill Wechsler	Safety and Security As FDA looks to balance risks and benefits, more regulations are on the horizon.
National Defense August 2009 Grace V. Jean	Taking a Shot at Nuclear Terrorism Cleveland BioLabs Inc. of Buffalo, N.Y., has developed a radiation countermeasure, called Protectan CBLB502. When given as a single injection, as many as 80 percent of those exposed to total body irradiation could survive.
<Older 5761-5770 Newer> Return to current articles.